Literature DB >> 17171762

To switch or not to switch--the opposing roles of TACI in terminal B cell differentiation.

Ulrich Salzer1, Stephanie Jennings, Bodo Grimbacher.   

Abstract

The TNF superfamily ligands BAFF and APRIL and their three receptors BAFFR, BCMA, and TACI comprise a network that is critically involved in the development and function of humoral immunity. Failure of this complex system is associated with autoimmune disease, B lymphocyte tumours, and antibody deficiency. While BAFF:BAFFR interactions control peripheral B cell survival and homeostasis, BCMA function seems limited to the survival of long-lived bone marrow plasma cells. The functional activity of the third receptor TACI is, however, ambiguous: while TACI-/- mice predominantly develop autoimmunity and lymphoproliferation, TACI deficiency in humans primarily manifests itself as an antibody deficiency syndrome. An article in this issue of the European Journal of Immunology demonstrates a negative regulation via TACI in human B cells by using TACI specific antibodies. B cell proliferation, class switch recombination, and Ig production induced by various stimuli were inhibited via TACI. Within the BAFF/APRIL network, the expression of the receptors and ligands is spatially, as well as temporally, highly regulated at various stages of B cell development and function. Defining the exact contribution of TACI stimulation by specific triggers in vitro enables us to better understand the complex, context-dependent responses initiated by TACI in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17171762     DOI: 10.1002/eji.200636914

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

2.  TACI mutations and disease susceptibility in patients with common variable immunodeficiency.

Authors:  A E J Poodt; G J A Driessen; A de Klein; J J M van Dongen; M van der Burg; E de Vries
Journal:  Clin Exp Immunol       Date:  2008-12-11       Impact factor: 4.330

Review 3.  Common variable immunodeficiency: etiological and treatment issues.

Authors:  Sean Deane; Carlo Selmi; Stanley M Naguwa; Suzanne S Teuber; M Eric Gershwin
Journal:  Int Arch Allergy Immunol       Date:  2009-07-01       Impact factor: 2.749

4.  A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.

Authors:  Mamta Gupta; Stacey R Dillon; Steven C Ziesmer; Andrew L Feldman; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Blood       Date:  2009-03-25       Impact factor: 22.113

5.  Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion.

Authors:  Xinrui Li; Kaihong Su; Chuanyi Ji; Alexander J Szalai; Jianming Wu; Yan Zhang; Tong Zhou; Robert P Kimberly; Jeffrey C Edberg
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

Review 6.  Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment.

Authors:  Jean L Scholz; Michael P Cancro
Journal:  Immunol Lett       Date:  2012-02-06       Impact factor: 3.685

7.  RhoA of the Rho family small GTPases is essential for B lymphocyte development.

Authors:  Shuangmin Zhang; Xuan Zhou; Richard A Lang; Fukun Guo
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

Review 8.  B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

Authors:  P J Hengeveld; M J Kersten
Journal:  Blood Cancer J       Date:  2015-02-27       Impact factor: 11.037

Review 9.  Current Clinical Trials in Pemphigus and Pemphigoid.

Authors:  Kentaro Izumi; Katja Bieber; Ralf J Ludwig
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

10.  In vivo identification of novel STAT5 target genes.

Authors:  Beth Basham; Manjiri Sathe; Jeffrey Grein; Terrill McClanahan; Annalisa D'Andrea; Emma Lees; Anne Rascle
Journal:  Nucleic Acids Res       Date:  2008-05-20       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.